Display options
Cite
Fossler MJ, Collins DA, Ino H, et al. Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers. J Drug Assess. 2015;4(1):24-9doi: 10.3109/21556660.2015.1067219.
Fossler, M. J., Collins, D. A., Ino, H., Sarai, N., Ravindranath, R., Bowen, C. L., & Burns, O. (2015). Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers. Journal of drug assessment, 4(1), 24-9. https://doi.org/10.3109/21556660.2015.1067219
Fossler, Michael J, et al. "Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers." Journal of drug assessment vol. 4,1 (2015): 24-9. doi: https://doi.org/10.3109/21556660.2015.1067219
Fossler MJ, Collins DA, Ino H, Sarai N, Ravindranath R, Bowen CL, Burns O. Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers. J Drug Assess. 2015 Jul 14;4(1):24-9. doi: 10.3109/21556660.2015.1067219. eCollection 2015. PMID: 27536459; PMCID: PMC4937626.
Copy Download .nbib Format: NLM
Share it on

J Drug Assess. 2015 Jul 14;4(1):24-9. doi: 10.3109/21556660.2015.1067219. eCollection 2015.

Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers.

Journal of drug assessment

Michael J Fossler, David A Collins, Hiroko Ino, Nobuaki Sarai, Ramiya Ravindranath, Chester L Bowen, Olivia Burns

Affiliations

  1. Clinical Pharmacology Modeling and Simulation, Quantitative Sciences, GlaxoSmithKline, King of Prussia, PA, USA.
  2. Clinical Statistics, Quantitative Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA.
  3. Medicines Development (Immuno-Inflammation), Development & Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan.
  4. Statistics and Programming, Quantitative Sciences, GlaxoSmithKline, Bangalore, India.
  5. Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, PA, USA.
  6. Clinical Pharmacology Science and Study Operations, GlaxoSmithKline Australia Pty Ltd, Abbotsford, Victoria, Australia.

PMID: 27536459 PMCID: PMC4937626 DOI: 10.3109/21556660.2015.1067219

Abstract

OBJECTIVE: To evaluate the bioequivalence of five 0.1 mg dutasteride capsules to one 0.5 mg dutasteride capsule in healthy adult male subjects under fasting conditions.

METHODS: This was a single-center, open-label, randomized, single dose, two-way cross-over study (ClinicalTrials.gov identifier NCT01929330). Thirty-six healthy male subjects aged 18-65 years received 5 × 0.1 mg dutasteride softgel capsules and 1 × 0.5 mg dutasteride softgel capsule in a randomized order, with a minimum washout of 28 days between each drug administration. Serial blood samples were collected for the measurement of serum dutasteride concentrations by a validated HPLC-MS/MS method. Dutasteride pharmacokinetic parameters were calculated using non-compartmental analysis. Maximum concentration (Cmax) and area under the concentration-time curve to the last quantifiable concentration (AUC[0-t]) were compared between treatments. Safety and tolerability were monitored throughout the study.

RESULTS: Five 0.1 mg dutasteride capsules were demonstrated to be bioequivalent to 1 × 0.5 mg dutasteride capsule, as the 90% confidence intervals for Cmax and AUC were within the accepted bioequivalence range of 0.80-1.25. The geometric least squares means ratios and associated 90% confidence intervals for 5 × 0.1 mg capsules vs 1 × 0.5 mg capsule were 1.01 (0.97-1.05) for Cmax and 0.91 (0.84-1.00) for AUC(0-t). Adverse events (AEs) were reported for 42% (15/36) and 36% (12/33) of subjects in the 5 × 0.1 mg and 1 × 0.5 mg dosing sessions, respectively. The most frequent AE for both treatments was headache. No subject had a serious AE.

CONCLUSIONS: Five 0.1 mg dutasteride capsules were shown to be bioequivalent to one 0.5 mg dutasteride capsule in healthy adult male subjects under fasted conditions, suggesting that the two dose strengths can be interchanged. Both treatments were generally well tolerated in healthy male subjects.

Keywords: Bioequivalence; Clinical trial; Dutasteride; Male; Pharmacokinetics

References

  1. Eur Urol. 2003 Jul;44(1):82-8 - PubMed
  2. J Am Acad Dermatol. 2006 Dec;55(6):1014-23 - PubMed
  3. J Clin Invest. 1993 Aug;92(2):903-10 - PubMed
  4. J Am Acad Dermatol. 2010 Aug;63(2):252-8 - PubMed
  5. BMJ. 1998 Sep 26;317(7162):865-9 - PubMed
  6. Curr Top Med Chem. 2006;6(5):405-21 - PubMed
  7. Dermatol Clin. 1996 Oct;14(4):697-711 - PubMed
  8. J Clin Invest. 1992 Jan;89(1):293-300 - PubMed
  9. J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3 - PubMed
  10. Expert Opin Pharmacother. 2013 Jul;14(10):1399-408 - PubMed
  11. Annu Rev Biochem. 1994;63:25-61 - PubMed
  12. J Invest Dermatol. 1997 Sep;109(3):296-300 - PubMed

Publication Types